Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cannabis Testing topic
No spam. Unsubscribe anytime.
Sponsor offers matrix-based testing plan to require medical cannabis testing and tracking; committee tables bill for more work
Summary
Representative Graham circulated a strike-and-replace amendment for LD 18 47 that would align medical and adult-use testing and implement a matrix (route-of-exposure) model, caregiver exemptions and mandatory tracking; proposed potency caps alarmed some members and the committee tabled the proposal for further technical work.
Representative Natalie Graham presented a strike-and-replace amendment to LD 18 47 that would institute mandatory testing and statewide inventory tracking for the Maine medical cannabis program, aligning many definitions and testing standards with the adult-use program while adding a matrix-based approach to testing ranges.
Graham said the matrix distinguishes routes of exposure (inhalation, ingestion, topical, etc.) and applies different standardized mandatory tests and tolerances appropriate to how product is used. The amendment would require testing for potency and for harmful contaminants (including specified molds and pesticide screens), establish uniform definitions across adult-use and medical statutes, require reporting of test results to OCP and retention of records for six years, and permit OCP to audit results and sample for verification.
To reduce burdens on small caregivers, the amendment exempts small-scale caregivers who meet criteria on cultivated area and who do not engage in wholesale transactions; untested product must be labeled with a clear warning that it has not been tested for contaminants. Graham said the change reflects stakeholder outreach and attempts to balance patient safety with caregiver viability.
A contentious technical detail drew immediate attention: the draft sets adult-use-style potency limits'no more than 10 mg THC per serving and no more than 200 mg THC per package'which some members warned would be incompatible with medical dosing for some patients. Representative Boyer asked whether a patient requiring 500 mg would be forced to consume dozens of 10-mg servings to reach the same dose; analysts acknowledged the math was accurate for the draft language and members flagged it as a possible unintended consequence.
Committee members differed sharply over whether the committee needed another public hearing or whether further work sessions and stakeholder invitations would suffice. Given the technical complexity and recent enforcement questions around adult-use testing, the committee voted to table the bill to allow time for more detailed drafting and review.
